Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL

被引：14
|
作者：
Wierda, W [1 ]
Faderl, S [1 ]
O'Brien, S [1 ]
Cortes, J [1 ]
Ferrajoli, A [1 ]
Giles, F [1 ]
Andreff, M [1 ]
Koller, C [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.340.340
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
340
引用
收藏
页码：101A / 101A
页数：1
相关论文
共 50 条
  • [41] FLUDARABINE, CYCLOPHOSPHAMIDE AND LENALIDOMIDE IN RELAPSED/REFRACTORY PATIENTS WITH CLL, PRELIMINARY RESULTS OF THE PHASE1-2 GIMEMA CLL0606 STUDY
    Mauro, F. R.
    Carella, A. M.
    Vignetti, M.
    Orlando, S. M.
    Liberati, A. M.
    Molica, S.
    Belsito, V.
    Cortellezzi, A.
    Zaia, F.
    Specchia, G.
    Tosi, P.
    Campanelli, M.
    Iannella, E.
    Trastulli, F.
    Nanni, M.
    Marinelli, M.
    Graziosi, A.
    Cuneo, A.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2014, 99 : 319 - 319
  • [42] FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone
    Dornan, David
    Spleiss, Olivia
    Yeh, Ru-Fang T.
    Duchateau-Nguyen, Guillemette
    Robak, Tadeusz
    Moiseev, Sergey I.
    Dmoszynska, Anna
    Solal-Celigny, Philippe
    Warzocha, Krzysztof
    Loscertales, Javier
    Catalano, John
    Afanasiev, Boris V.
    Larratt, Loree
    Rossiev, Viktor A.
    Bence-Bruckler, Isabelle
    Geisler, Christian H.
    Montillo, Marco
    Wenger, Michael K.
    Weisser, Martin
    BLOOD, 2009, 114 (22) : 923 - 923
  • [43] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
  • [44] Fludarabine and rituximab for relapsed or refractory hairy cell leukemia
    Gerrie, Alina S.
    Zypchen, Leslie N.
    Connors, Joseph M.
    BLOOD, 2012, 119 (09) : 1988 - 1991
  • [45] Alemtuzumab (continuous infusion followed by subcutaneous injection) plus rituximab is active in patients (PTS) with relapsed/refractory chronic lymphocytic leukemia (CLL) - An update of the MDACC experience
    Faderl, S
    Wierda, W
    Ferrajoli, A
    O'Brien, S
    Garcia-Manero, G
    Thomas, D
    Kantarjian, H
    Browning, M
    Lerner, S
    Keating, M
    ANNALS OF ONCOLOGY, 2005, 16 : 91 - 91
  • [46] Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
    Badoux, Xavier C.
    Keating, Michael J.
    Wang, Xuemei
    O'Brien, Susan M.
    Ferrajoli, Alessandra
    Faderl, Stefan
    Burger, Jan
    Koller, Charles
    Lerner, Susan
    Kantarjian, Hagop
    Wierda, William G.
    BLOOD, 2011, 118 (08) : 2085 - 2093
  • [47] FLUDARABINE REFRACTORY AND VERY ADVANCED CLL: VALUE OF RITUXIMAB MONOTHERAPY
    Lepretre, S.
    Leblond, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 600 - 601
  • [48] Phase II study of talabostat and rituximab in fludarabine/rituximab-resistant or refractory patients with CLL.
    Khan, K. D.
    O'Brien, S.
    Rai, K. R.
    Brown, J. R.
    Abboud, C.
    Hurd, D. D.
    Conkling, P.
    Yang, Z.
    Haltom, E. J.
    Uprichard, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [49] Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL)
    Wierda, W. G.
    Kipps, T.
    Mayer, J.
    Stilgenbauer, S.
    Robak, T.
    Williams, C. D.
    Furman, R.
    Chan, G.
    Russell, C.
    Osterborg, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
    Panovska, Anna
    Smolej, Lukas
    Lysak, Daniel
    Brychtova, Yvona
    Simkovic, Martin
    Motyckova, Monika
    Vodarek, Pavel
    Lindtnerova, Michaela
    Trbusek, Martin
    Malcikova, Jitka
    Pospisilova, Sarka
    Mayer, Jiri
    Doubek, Michael
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (06) : 479 - 485
12345